Trial Profile

A Phase I Study Evaluating the Safety, Tolerability, Efficacy, and Pharmacokinetics of SCB-313, a Fully-Human TRAIL-Trimer Fusion Protein, for the Treatment of Malignant Ascites

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 18 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rilunermin alfa (Primary)
Indications Malignant ascites; Solid tumours
Focus Adverse reactions
Sponsors Clover Biopharmaceuticals

Most Recent Events

05 May 2022 Status changed from active, no longer recruiting to completed.
13 Apr 2022 Results of pooled analysis from two phase 1 trials (NCT03443674 and NCT04051112) presented at the 113th Annual Meeting of the American Association for Cancer Research
12 Jan 2022 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com